The FDA published a 68-page review of BPC-157, and they found one clinical trial across the whole orthopedic literature: 17 patients, who received BPC-157 mixed with a second peptide
BPC-157 Mechanism Growth factor upregulation increases expression of VEGF, FGF, and other growth factors at injury sites Angiogenesis promotes formation of new blood vessels, improving nutrient and oxygen delivery to damaged tissue Nitric oxide modulation regulates blood flow and inflammation through the NO system Gut-brain axis derived from gastric juice, with particular affinity for GI tissue repair TB-500 Mechanism Actin upregulation increases production of actin, a key protein for cell structure, migration, and repair Cell migration promotes movement of repair cells (fibroblasts, endothelial cells) to the injury site Anti-inflammatory reduces inflammatory cytokines and dampens excessive immune response Systemic reach low molecular weight allows it to travel through tissues more easily than most peptides Combined Effect Multi-pathway repair addresses both the infrastructure (blood supply, growth factors) and the workforce (cell migration, tissue building) Broader tissue coverage BPC-157's gut and tendon affinity pairs with TB-500's muscle and joint effects Faster onset simultaneous action on different repair bottlenecks may accelerate overall healing timeline Reduced inflammation both peptides modulate inflammation through different pathways This isn't theoretical stacking the mechanisms are genuinely complementary
SS, AP, TD, and HV: formal analysis
Semax (cerebral ischemia, migraine, trigeminal neuralgia)
